Streams

Barry Meier

New York Times reporter, author of an article in today’s paper about Washington State lawmakers and their efforts to regulate of prescription painkillers.

Barry Meier appears in the following:

Please Explain: Pain Medication

Friday, August 02, 2013

This week we're following up on Please Explain: Pain to find out more about pain killers. Barry Meier, New York Times reporter and author of A World of Hurt: Fixing Pain Medicine’s Biggest Mistake, talks about how pain medications work, how over the counter analgesics compare to prescription pain killers, and the problems of pain killer addiction.

Comments [18]

Food vs. Drug

Wednesday, November 28, 2012

Barry Meier, reporter for The New York Times covering business, public health and the law, talks about the FDA's investigation into energy drink-related deaths, and how the agency regulates products that straddle the line between food and drug.

Comments [9]

Unapproved Hip Replacement Caused Pain Worldwide

Wednesday, February 15, 2012

In 2009, the Food and Drug Administration rejected an artificial hip manufactured by Johnson & Johnson. However, the company continued to sell the hip replacement in Europe and marketed a related model stateside. More than 90,000 patients worldwide used these faulty devices, and resulted in painful corrective surgery for many. In the wake of an August 2010 recall and thousands of lawsuits, Johnson & Johnson has lost at least $3 billion.

Comment

Fail: Hip Replacements

Tuesday, October 04, 2011

Barry Meier, reporter for New York Times business, public health and law, discusses his reports on the problems with metal-on-metal hip replacement devices.

Comments [15]

When a Solution Becomes a Problem: Doctors and Lawmakers on Opiate Painkillers

Thursday, July 29, 2010

Today an FDA advisory panel meets with lawmakers to hammer out voluntary best practices for doctors who prescribe opiates. The regulation of opioid drugs like Oxycontin has loosened in recent years, as patient advocates asked for powerful narcotic painkillers for end-of-life care and cancer treatments. But in loosening restrictions for such cases, the FDA opened a window for wider prescriptions — and for abuse.

Comments [3]